Skip to main content
Premium Trial:

Request an Annual Quote

Merck s Bennett Shapiro Joins Elixir Board; Paradigm Gets Computational Systems Biology Director from Morphochem; Rescentris Appoints Four Executives

NEW YORK, April 16 - Bennett Shapiro of Merck has been appointed to the board of Elixir Pharmaceuticals, a Boston-area genomics-based drug discovery company, Elixir said today.

 

Shapiro currently serves as executive vice president of worldwide licensing and external research at Merck.   He has been at Merck since 1990, when he joined as executive vice president of basic research. Previously, he served as professor and chairman in the department of biochemistry at the University of Washington.

 


 

Brian Bullard has been appointed senior director of computational systems biology at Paradigm Genetics, the company said April 15. The company also appointed Michael Liebman, director of biomedical informatics at the Abramson Family Cancer Research Institute at the University of Pennsylvania School of Medicine, to its scientific advisory board.

 

Bullard comes to Paradigm from Morphochem, where he integrated the companies cheminformatics database and its genomics initiative, and initiated statistical-based data acceptance methods. He previously served as vice president and chief information officer at AxCell Biosciences, which is a subsidiary of Cytogen.

 

Liebman has moved to academia from pharma, most recently serving as global head of computational genetics at Roche Biosciences, and previously as director of biomedical informatics and pharmacogenomics at Wyeth-Ayerst. He also has worked at Vysis as director of bioinformatics.

 


 

Rescentris has appointed four new executives, the company said April 10. Eldred Ribiero is director of software development; Charles Guo is director of biomedical informatics; Wolfgang Rumpf is director of product development; and Lorie Karnath is managing director, international and chairperson of the scientific advisory board.

 

All three come to Rescentris, a Columbus, Ohio, life sciences informatics firm, from LabBook, where they all held similar positions. Rescentris was formed by former LabBook executives.

The Scan

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.

Sequencing Study Leads to Vaccine Target in Bacteria Behind Neonatal Meningitis

Researchers eBioMedicine track down potential vaccine targets with transposon sequencing on mutant bacteria causing neonatal meningitis in mouse models of the disease.

Multiple Myeloma Progression Influenced by Immune Microenvironment Expression

Researchers in NPJ Genomic Medicine compare RNA sequencing profiles of 102,207 individual cells in bone marrow samples from 18 individuals with rapid or non-progressing multiple myeloma.

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.